SCHEMBL10078401

SCHEMBL10078401

O=c1c(Cc2ccccc2)c(N2CCNCC2)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.50
HTR6 P50406 3/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
SIGMAR1 Q99720 3/20 0.45
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
ADRB1 P08588 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
ITGA2B P08514 1/20 0.43
DPP4 P27487 2/20 0.42
HTR1A P08908 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12660318 0.88 HTR1A (0.50) TAAR1HTR6HTR2AHTR2CSIGMAR1
SCHEMBL9272387 0.74 HTR6 (0.48) TAAR1HTR6HTR2AHTR2CHTR2B
SCHEMBL10077099 0.72 HTR6 (0.49) HTR6HTR2AHTR2BSIGMAR1HTR3E
SCHEMBL6560078 0.71 SIGMAR1 (0.68) TAAR1HTR6SIGMAR1HTR3EHTR3B
Hydrochloric Acid SCHEMBL2881381 0.70 SIGMAR1 (0.66) TAAR1HTR6SIGMAR1HTR3EHTR3B
SCHEMBL9272777 0.70 HTR6 (0.50) TAAR1HTR6HTR2AHTR2CHTR2B
SCHEMBL9272779 0.70 HTR6 (0.52) TAAR1HTR6HTR2ASIGMAR1HTR3E
SCHEMBL6164646 0.69 HTR1A (0.60) TAAR1HTR6HTR2AHTR2CHTR2B
SCHEMBL27701893 0.69 CETP (0.47) TAAR1HTR6HTR2AHTR2CHTR2B
Hydrochloric Acid SCHEMBL9654609 0.68 HTR1A (0.59) TAAR1HTR6HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013170-B1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2012-06-27 EP disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
WO-2007127731-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-08 WO disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents MAVS, MTAP, SAMHD1 TAAR1 4812/4885HTR6 1391/4885HTR2A 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.